AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01884519 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix/Influsplit SSW® (2013-2014 season)
Description: 1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
Study NCT01853566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone
Description: GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
Study NCT00879450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: booklet given to parents for home exercises
Study NCT00879450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet
Description: booklet given to parents for home exercises
Study NCT04093037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #1: Non Invasive Break-Up Time (NIBUT)
Description: A LacryDiag examination without dye will be realized. All measurements are made without contact. It's calculates the Non Invasive Break-Up Time (NIBUT), Tear Meniscus (TM) height (in millimeters) and number of Meibomian Gland.~These are different pictures taken with LacryDiag and analyzed.
Study NCT04093037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #2: MicroInstillation Break-Up Time (MIBUT) + Oxford score
Description: The MicroInstillation of fluorescein Break-Up Time (MIBUT) will be calculated by manual MIBUT and LacryDiag MIBUT.~The Oxford score will be calculated. It's used to clinically determine the severity of dry eyes with minimum score at 0 (none) and maximum score at 5 (very severity).
Study NCT04093037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #3: Standard Break-Up Time (SBUT)
Description: The Standard Break-Up Time (SBUT) with fluorescein macroinstillation will be calculated by manual SBUT and LacryDiag SBUT.
Study NCT04093037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Time #4: Schirmer test
Description: The Schirmer test will be performed. It consists of applying the end of a small strip of blotting paper behind the lower eyelid and examining the strip after 5 minutes.
Study NCT04093037 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire to the patient
Description: A satisfaction questionnaire to the patient will be completed at the end of the participation at the study.
Study NCT02418637 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Worksite screening for DM, HTN and hyperlipidemia
Description: Six monthly visits to worksite to perform screenings
Study NCT04018339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules
Study NCT04018339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing an inert placebo
Study NCT02196675 — intervention group
Intervention type: DEVICE
Intervention: Endocutter
Description: The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
Study NCT00805415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
Study NCT00805415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (SH T00658L)
Description: Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
Study NCT01330901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
Study NCT01982591 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01982591 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT04579549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saliva Assay
Description: saliva assay test for high concentrations of SARS-CoV-2
Study NCT03651843 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Women who have recently given birth in the Lille metropolitan area fill in a self-administered questionnaire asking them about their perception of occupational risk during pregnancy and their knowledge of their right to work during pregnancy.
Study NCT02349126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-520 Injection
Description: ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
Study NCT04972877 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment group protocol
Description: For treatment group, two groups of acupoints will be used alternatively. The first group consists of some acupoints. The patients will be asked to stay in supine position. Disposable sterilized needles (Size: 0.25\*40/50 mm) will be inserted into a depth of 15\~35 mm and stimulated manually to evoke needle sensation. And then some acupoints will be thereafter connected to electrical stimulators and stimulated with low-frequency and the maximum tolerated intensity of the patients. The other needles without electrical stimulators will be manually stimulated to evoke Deqi every 10 minutes.~The second group consists of other acupoints. Patients will be asked to stay in prone position. The stimulation will be in the same way as the first group.
Study NCT04972877 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group protocol
Description: For control group, four pseudo-acupoints are used, with two points on each shoulder and the two on each upper arm, which are not located on any meridians. The patients will be asked to stay in supine position and keep the whole body relaxed and comfortable. Disposable sterilized needles (Size: 0.18\*25 mm) will be inserted superficially to a depth of \< 5 mm without any manual stimulus and the needle sensation (Deqi in TCM) should not be evoked. Electrodes are connected to the needles, but the stimulators should be turned on at an intensity of zero. Each intervention lasts for 30 minutes.
Study NCT01755832 — intervention group
Intervention type: PROCEDURE
Intervention: Pool exercise
Description: Group exercise in heated pool one hour per week for 12 weeks.
Study NCT01466842 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Catheter ablation using cryothermia
Description: Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
Study NCT04120688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D generated tooth replica
Description: 3D generated tooth replicas are compared to conventional procedure
Study NCT01748799 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sativex
Description: All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
Study NCT01748799 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
Study NCT03669523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab-nivolumab combination
Description: * Denosumab: 120 mg every 4 weeks subcutaneously~* Nivolumab: 240mg intravenously on day 1 every 2 weeks
Study NCT01032629 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule taken orally (by mouth) once daily
Study NCT01032629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily
Study NCT01032629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754) 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily
Study NCT01617538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 40mg per day,duration for 24 weeks
Study NCT03371355 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Matched with ISIS 703802)
Study NCT03371355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 703802 40 mg
Description: ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
Study NCT03371355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 703802 80 mg
Description: ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
Study NCT03371355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 703802 20 mg
Description: ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
Study NCT02236689 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non operative
Description: no surgical intervention
Study NCT02236689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic tennis elbow release
Description: Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
Study NCT01511731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine Tablets 40 mg
Study NCT01511731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pepcid
Description: 40mg tablets
Study NCT00476099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
Description: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
Study NCT00476099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI
Description: Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
Study NCT00476099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 µg plus formoterol 6 µg DPI
Description: two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
Study NCT00476099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200 µg plus formoterol 6 µg DPI
Description: two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
Study NCT00476099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol 12 µg DPI
Description: one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
Study NCT00476099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol 12 µg DPI
Description: one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
Study NCT04920240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cleaning and disinfection mode for surfaces with high frequency contact
Description: According to the results of the survey on the status of high frequency contact surface, the corresponding frequency and method of cleaning and disinfection are determined. Set up a multidisciplinary quality control team.
Study NCT04920240 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine procedure
Description: clean the high frequency contact surface like other surfaces
Study NCT02829879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8% arginine/1450ppm sodium monofluorophosphate dentifrice
Study NCT02829879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% potassium nitrate/2500ppm sodium fluoride dentifrice
Study NCT03841552 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Feedback
Description: An inertial measurement unit (IMU) system is the basis of the augmented feedback (AF) system, where the IMU-system communicates with a laptop using a bluetooth dongle. The corresponding software includes therapeutic games. Movements of the lower back and pelvis by the patient are used to control an avatars movement or the graphical interface in computer exercises. The AF-system provides real-time feedback regarding the patient's performance and helps to rectify incorrect execution of the exercises. The intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
Study NCT03841552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Conventional impairment-specific physiotherapy exercises for low back pain patients.The control intervention took place at a physiotherapy clinic and in an home environment. In the physiotherapy clinic the patients exercised under the supervision of the physiotherapists. They continued the exercises at home as home exercises.
Study NCT00799526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Ex Vivo Conjunctival for Symblepharon Transplantation
Description: Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
Study NCT00799526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ex Vivo Conjunctival for Symblepharon Transplantation
Description: The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
Study NCT04329026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glasses
Description: The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.
Study NCT04329026 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
Study NCT02235649 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Cognition therapy ( Psychological Therapy)
Study NCT02210156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omniplus Supreme
Description: Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
Study NCT02210156 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
Study NCT03501862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (psychosis)
Description: A small group intervention is based on a structured and validated protocol that will include mindfulness practice, cognitive skills
Study NCT03501862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation (psychosis)
Description: A small group intervention will be focusing on understanding of psychosis, treatment, relapse prevention and useful information and resources.
Study NCT03462251 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ribociclib and aromatase inhibitor or fulvestrant
Description: Combination of ribociclib and aromatase inhibitor or fulvestrant
Study NCT03462251 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab
Description: Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab
Study NCT03403400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRWP Group
Description: The VRWP group will have VR with an instruction to increase their number of steps daily to at least 3,000 steps using the pedometer (VR plus walking plus pedometer group). They will receive pedometers (Fitbit Zip), instructions on how to use the pedometer, step log forms, with home instruction handout to walk more at least more than ten minutes at a time. The participants will record on their activity log the number of steps shown on the step display at the end of the day. The daily step log form will be given to the research staff every visit for recording. The research staff will encourage their participants to increase their daily steps at least 10% until they achieve at least 3,000 steps daily.
Study NCT03403400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VRW Group
Description: The VR (control) group will follow the conventional VR physical therapy without the encouragement of walking and without specification of walking in the home exercise program.
Study NCT03429868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: integrated PET/MRI
Description: The participants receive an integrated 18F-FDG PET/MRI scan in addition to the conventional 18F-FDG PET/CT on the same day during tumor staging.~Whole body 18F-FDG PET/CT is performed one hour after injection of 10mCi of 18F-FDG. 18F-FDG PET/MRI is done after the PET/CT scan. And no additional 18F-FDG is given to the patients in the PET/MRI scan.
Study NCT02683369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blood Builder®/Iron Response®
Description: The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.~One tablet will be taken once a day offering a total daily serving of:~* 15 mg of Vitamin C~* 400 mcg of Folate~* 30 mcg Vitamin of B-12~* 26 mg of Iron~* 125 mg of Beet Root
Study NCT01124825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IGEL
Description: iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
Study NCT01124825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: King airway
Description: KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
Study NCT02604004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epivir ® tablet 150-mg single dose (drug reference)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study NCT02604004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epivir ® tablet 150-mg single dose (drug reference)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study NCT02604004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine 150-mg tablet single dose (drug test)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study NCT02604004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine 150-mg tablet single dose (drug test)
Description: Bioequivalence lamivudine 150 mg tablets fasting condition
Study NCT02747485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Study NCT02747485 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
Study NCT02747485 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myocardial biopsy
Study NCT02747485 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood samples
Description: extract DNA to look for genomic mutations associated with the disease.
Study NCT00977470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg taken orally once daily
Study NCT00977470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 1000 mg taken orally once daily after erlotinib
Study NCT04209231 — intervention group
Intervention type: OTHER
Intervention: 1.25(OH)2D3
Study NCT04209231 — intervention group
Intervention type: OTHER
Intervention: 25(OH)D
Study NCT02965378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV